In Reply We thank Wang et al for their interest in our recent article.1 The information requested by Wang et al is in fact in the published manuscript. Regarding which trials of the 11 were included in the network meta-analysis, we refer Wang et al to the original manuscript, in which we cited all included trials for each comparison. In addition, as mentioned in the Study Selection paragraph in the Results section,1 all 12 trials were included in the quantitative analysis except for the Combined Oxaliplatin Neurotoxicity Prevention Trial (CONCEPT). Figure 2 of our article1 clearly shows the direct comparison with efficacy data as reported by the included studies. For the studies where the data were not available (as in the AIO 0207, Stop and Go, and OPTIMOX2 trials), imputed hazard ratios were included in the network meta-analysis.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Sonbol MB, Murad MH, Bekaii-Saab T. The Role of Maintenance Therapy in Metastatic Colorectal Cancer—Reply. JAMA Oncol. 2020;6(6):937–938. doi:10.1001/jamaoncol.2020.0583
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: